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Thigh-length compression stockings and DVT after stroke
Deep vein thrombosis (DVT) and pulmonary embolism 
(PE) are key complications after stroke that can lead to 
substantial morbidity and mortality. Rates of venous 
thromboembolism (VTE) were high in the past but have 
fallen,1 reﬂ ecting increased use of early rehydration, 
mobilisation, and aspirin.2,3 An additional intervention 
is the use of graduated compression stockings (GCS), 
the eﬃ  cacy of which, although shown for surgery,4 is 
unproven in stroke.1,5
In The Lancet today, Martin Dennis and colleagues6 
present the results of the CLOTS 1 trial, the ﬁ rst large 
assessment of the safety and eﬃ  cacy of thigh-length GCS 
in patients with recent stroke. The CLOTS 1 trial is vitally 
important for stroke care. 2518 patients were recruited 
from 64 centres in Australia, Italy, and the UK (in the 
latter case, beneﬁ tting from the UK Stroke Research 
Network) within 3 days of admission after stroke, and 
were representative of patients entering stroke services. 
The primary outcome was symptomatic or asymptomatic 
DVT detected on compression Doppler ultrasound, or 
symptomatic DVT, in the popliteal or femoral veins 
occurring within 30 days of randomisation. The trial found 
that GCS did not reduce DVT, compared with no GCS 
(absolute reduction 0·5%, 95% CI –1·9% to 2·9%, number 
needed to treat 200). GCS did not aﬀ ect key secondary 
outcomes, including components of the primary 
outcome, as well as PE, VTE, and death. Importantly, GCS 
did not seem to be beneﬁ cial in prespeciﬁ ed subgroups: 
patients treated early, those with leg weakness, and 
those not given concomitant anticoagulation. Equally 
importantly, the use of GCS was associated with a four-
fold increase in skin ulcers and necrosis, and a non-
signiﬁ cant increase in lower-limb ischaemia. These results 
are supported by an earlier observational study that also 
found no beneﬁ t with GCS.7
These ﬁ ndings suggest that GCS do not work after 
stroke, although they do work after surgery.4 This 
might reﬂ ect diﬀ erences in the age of patients, dura-
tion of immobility, and comorbidities. Alternatively, 
CLOTS 1 could have obtained the wrong result. First, the 
trial might have been too small since it was only powered 
to detect a 4% absolute reduction in the primary 
outcome. However, the logistics and health economics of 
administering GCS to reduce DVT by, say, 2% are probably 
not worthwhile—for example, 24 stroke patients would 
need about 0·3 of a nurse per day just to measure and ﬁ t 
GCS, with an additional cost per patient of about £20 for 
the stockings (assuming three pairs per patient). Second, 
the rate of proximal DVT (the type most likely to lead to 
PE) was lower than expected (10% vs 12%), which will 
have reduced the power of the study. Third, the trial was 
necessarily unblinded; however, the detection of DVT was 
made blinded to therapy by removing GCS with suﬃ  cient 
time before ultrasound to allow skin indentations to 
disappear. Lack of treatment blinding could mean that 
investigators managed patients diﬀ erently; the 0·8% 
excess use of anticoagulation in patients randomised to 
avoid GCS might indicate such a bias, although this is 
unlikely to have inﬂ uenced the overall ﬁ ndings. Fourth, 
although centres were trained in the sizing and ﬁ tting 
of GCS, it is likely that both trial and clinical practice can 
result in the incorrect use of GCS; this practice would 
be ineﬀ ective or even hazardous. Last, compliance is 
important7 and the CLOTS 1 investigators report that this 
was only 79% in the ﬁ rst 14 days, and 73% up to 30 days.
What then should be used for VTE prophylaxis after 
stroke? CLOTS 2 is a comparison of thigh-length versus 
below-knee GCS, but this trial will now close early in 
view of the CLOTS 1 results. Intermittent pneumatic 
compression has also been studied5,8 and CLOTS 3 
is assessing this approach. Subcutaneous low-to-
medium dose heparin is eﬀ ective in reduction of VTE 
but unfortunately the reduction in PE, the primary 
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target for prevention, is matched by a similar increase 
in symptomatic intracerebral haemorrhage and the 
absolute rates of both events are similar.9–11 Worse still, 
the risk factors for VTE and symptomatic intracerebral 
haemorrhage are similar (eg, age and severity) so it is not 
possible to identify patients who are at high risk of VTE 
but not bleeding. Thus, prophylactic heparin cannot be 
recommended routinely after ischaemic stroke. However, 
low-molecular-weight heparin (which is more eﬀ ective 
than unfractionated heparin12 and only needs to be given 
once daily) should probably be used in patients who are 
at very high risk of VTE, such as those with previous VTE, 
known thrombophilia, or morbid obesity. 
In summary, GCS do not reduce DVT or overall VTE in 
patients with recent stroke; indeed, they damage the skin 
and might promote limb ischaemia. GCS should not be 
used after stroke and current guidelines13,14 will need to be 
amended. No speciﬁ c prophylaxis appears to be necessary, 
although early rehydration, mobilisation, and aspirin are 
key cornerstones of good stroke care. Prophylactic heparin 
should be used only in patients at very high risk of VTE; 
routine use, as currently recommended in guidelines,13,14 
is not appropriate because of the increased risk of 
intracerebral haemorrhage. The role of GCS now needs to 
be assessed urgently in other settings where they might 
also lack eﬃ  cacy, including in general medical patients.
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Understanding childhood sexual abuse in Africa
In The Lancet today, Avid Reza and colleagues present 
survey data on sexual violence in girls in Swaziland.1 In 
this survey, one of the few nationally representative 
samples from Africa, a third of girls and women aged 
13–24 years reported some form of sexual violence 
before age 18 years. Most perpetrators were men 
from their own household or in the immediate 
neighbourhood. These data should dispel perceptions 
that Africa has somehow escaped this global tragedy.
Sexual abuse of girls is widely reported by Africa’s popular 
press, often in the context of school.2 However, few studies 
have examined the frequency and nature of sexual violence 
in a representative manner from national or subnational 
populations. Where studies have been done, methodology 
and deﬁ nitional issues have limited comparability across 
sites. Nonetheless, the patterns from population and 
anecdotal studies in east Africa and elsewhere have found 
widespread sexual abuse of girls in patterns consistent 
with those reported from Swaziland.3–6 Reza and colleagues 
sought information about multiple types of sexual violence 
against girls, and their work can form a benchmark for 
future studies. Results from sexual-abuse surveys are 
thought to widely underestimate prevalence, because the 
trauma surrounding events might aﬀ ect recall and the 
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